Cargando…

CDDO-Me Alters the Tumor Microenvironment in Estrogen Receptor Negative Breast Cancer

The tumor microenvironment (TME) is an essential contributor to the development and progression of malignancy. Within the TME, tumor associated macrophages (TAMs) mediate angiogenesis, metastasis, and immunosuppression, which inhibits infiltration of tumor-specific cytotoxic CD8+ T cells. In previou...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ball, Michael S., Bhandari, Rajan, Torres, Gretel M., Martyanov, Viktor, ElTanbouly, Mohamed A., Archambault, Kim, Whitfield, Michael L., Liby, Karen T., Pioli, Patricia A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7162855/ https://www.ncbi.nlm.nih.gov/pubmed/32300202 http://dx.doi.org/10.1038/s41598-020-63482-x

Ejemplares similares

T Cells and CDDO-Me Attenuate Immunosuppressive Activation of Human Melanoma-Conditioned Macrophages
por: Torres, Gretel M., et al.
Publicado: (2022)

CDDO-Me Redirects Activation of Breast Tumor Associated Macrophages
por: Ball, Michael S., et al.
Publicado: (2016)

Synthesis and Anticancer Activity of CDDO and CDDO-Me, Two Derivatives of Natural Triterpenoids
por: Borella, Rebecca, et al.
Publicado: (2019)

The synthetic triterpenoids CDDO-TFEA and CDDO-Me, but not CDDO, promote nuclear exclusion of BACH1 impairing its activity
por: Casares, Laura, et al.
Publicado: (2022)

Prevention and Treatment of Experimental Estrogen Receptor – Negative Mammary Carcinogenesis by the Synthetic Triterpenoid CDDO-Methyl Ester and the Rexinoid LG100268
por: Liby, Karen, et al.
Publicado: (2008)

A Synthetic Triterpenoid CDDO-Im Inhibits Tumorsphere Formation by Regulating Stem Cell Signaling Pathways in Triple-Negative Breast Cancer
por: So, Jae Young, et al.
Publicado: (2014)

CDDO-Me: A Novel Synthetic Triterpenoid for the Treatment of Pancreatic Cancer
por: Deeb, Dorrah, et al.
Publicado: (2010)

The Triterpenoid CDDO-Me Inhibits Bleomycin-Induced Lung Inflammation and Fibrosis
por: Kulkarni, Ajit A., et al.
Publicado: (2013)

CDDO-Me inhibits tumor growth and prevents recurrence of pancreatic ductal adenocarcinoma
por: GAO, XIAOHUA, et al.
Publicado: (2015)

Preclinical evidences toward the use of triterpenoid CDDO-Me for solid cancer prevention and treatment
por: Wang, Yan-Yang, et al.
Publicado: (2014)

CDDO-Me reveals USP7 as a novel target in ovarian cancer cells
por: Qin, Dongjun, et al.
Publicado: (2016)

Inhibition of Telomerase Activity by Oleanane Triterpenoid CDDO-Me in Pancreatic Cancer Cells is ROS-Dependent
por: Deeb, Dorrah, et al.
Publicado: (2013)

Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties
por: Wang, Yan-Yang, et al.
Publicado: (2014)

CDDO-Me Protects Normal Lung and Breast Epithelial Cells but Not Cancer Cells from Radiation
por: El-Ashmawy, Mariam, et al.
Publicado: (2014)

Neuroprotective Effects of the Triterpenoid, CDDO Methyl Amide, a Potent Inducer of Nrf2-Mediated Transcription
por: Yang, Lichuan, et al.
Publicado: (2009)

Prevention of Prostate Cancer with Oleanane Synthetic Triterpenoid CDDO-Me in the TRAMP Mouse Model of Prostate Cancer
por: Gao, Xiaohua, et al.
Publicado: (2011)

Telomerase Reverse Transcriptase (TERT) is a Therapeutic Target of Oleanane Triterpenoid CDDO-Me in Prostate Cancer
por: Liu, Yongbo, et al.
Publicado: (2012)

Induction of Apoptosis in Pancreatic Cancer Cells by CDDO-Me Involves Repression of Telomerase through Epigenetic Pathways
por: Deeb, Dorrah, et al.
Publicado: (2014)

Hsp90 Is a Novel Target Molecule of CDDO-Me in Inhibiting Proliferation of Ovarian Cancer Cells
por: Qin, Dong-Jun, et al.
Publicado: (2015)

The Triterpenoid CDDO-Methyl Ester Redirects Macrophage Polarization and Reduces Lung Tumor Burden in a Nrf2-Dependent Manner
por: Moerland, Jessica A., et al.
Publicado: (2023)

Bardoxolone-Methyl (CDDO-Me) Impairs Tumor Growth and Induces Radiosensitization of Oral Squamous Cell Carcinoma Cells
por: Hermann, Cornelius, et al.
Publicado: (2021)

The Triterpenoid Nrf2 Activator, CDDO-Me, Decreases Neutrophil Senescence in a Murine Model of Joint Damage
por: Amirova, Kristiana M., et al.
Publicado: (2023)

Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway
por: Ryu, Keinosuke, et al.
Publicado: (2010)

Systems Level Analysis of Systemic Sclerosis Shows a Network of Immune and Profibrotic Pathways Connected with Genetic Polymorphisms
por: Mahoney, J. Matthew, et al.
Publicado: (2015)

CDDO-Me Abrogates Aberrant Mitochondrial Elongation in Clasmatodendritic Degeneration by Regulating NF-κB-PDI-Mediated S-Nitrosylation of DRP1
por: Lee, Duk-Shin, et al.
Publicado: (2023)

Induction of Mitosis Delay and Apoptosis by CDDO-TFEA in Glioblastoma Multiforme
por: Tsai, Tai-Hsin, et al.
Publicado: (2021)

CDDO-Me Selectively Attenuates CA1 Neuronal Death Induced by Status Epilepticus via Facilitating Mitochondrial Fission Independent of LONP1
por: Kim, Ji-Eun, et al.
Publicado: (2019)

CDDO and ATRA Instigate Differentiation of IMR32 Human Neuroblastoma Cells
por: Chaudhari, Namrata, et al.
Publicado: (2017)

Ca(2+) influx-mediated dilation of the endoplasmic reticulum and c-FLIP(L) downregulation trigger CDDO-Me–induced apoptosis in breast cancer cells
por: Jeong, Soo Ah, et al.
Publicado: (2015)

Bardoxolone-Methyl (CDDO-Me) Suppresses Androgen Receptor and Its Splice-Variant AR-V7 and Enhances Efficacy of Enzalutamide in Prostate Cancer Cells
por: Khurana, Namrata, et al.
Publicado: (2020)

CDDO-Me Attenuates Clasmatodendrosis in CA1 Astrocyte by Inhibiting HSP25-AKT Mediated DRP1-S637 Phosphorylation in Chronic Epilepsy Rats
por: Lee, Duk-Shin, et al.
Publicado: (2022)

Structure of the BTB Domain of Keap1 and Its Interaction with the Triterpenoid Antagonist CDDO
por: Cleasby, Anne, et al.
Publicado: (2014)

VISTA: A Target to Manage the Innate Cytokine Storm
por: ElTanbouly, Mohamed A., et al.
Publicado: (2021)

CDDO-Me Inhibits Microglial Activation and Monocyte Infiltration by Abrogating NFκB- and p38 MAPK-Mediated Signaling Pathways Following Status Epilepticus
por: Kim, Ji-Eun, et al.
Publicado: (2020)

Triterpenoid CDDO-Me induces ROS generation and up-regulates cellular levels of antioxidative enzymes without induction of DSBs in human peripheral blood mononuclear cells
por: Beinke, Christina, et al.
Publicado: (2020)

CDDO-Me Attenuates Vasogenic Edema and Astroglial Death by Regulating NF-κB p65 Phosphorylations and Nrf2 Expression Following Status Epilepticus
por: Kim, Min-Ju, et al.
Publicado: (2019)

A Point Mutation at C151 of Keap1 of Mice Abrogates NRF2 Signaling, Cytoprotection in Vitro, and Hepatoprotection in Vivo by Bardoxolone Methyl (CDDO-Me)
por: Gatbonton-Schwager, Tonibelle, et al.
Publicado: (2023)

The triterpenoid CDDO inhibits expression of matrix metalloproteinase-1, matrix metalloproteinase-13 and Bcl-3 in primary human chondrocytes
por: Elliott, Sarah, et al.
Publicado: (2003)

The Nrf2 triterpenoid activator, CDDO-imidazolide, protects kidneys from ischemia reperfusion injury in mice
por: Liu, Manchang, et al.
Publicado: (2013)

The synthetic triterpenoid CDDO-methyl ester modulates microglial activities, inhibits TNF production, and provides dopaminergic neuroprotection
por: Tran, Thi A, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_d3j538srh230g6acqcibmh57l9